Alzheimer’s Disease/Dementia News

Higher consumption of red meat, including processed red meat, was associated with a higher risk for cognitive decline and dementia, according to research published in Neurology.

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat individuals with mild cognitive impairment or mild dementia consistent with early stage Alzheimer’s disease.

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed that earlier initiation of the oral therapeutic led to significant disease slowing over 3 years.

Cases of dementia in the United States are expected to rise to 1 million per year by 2060, with Black individuals, women and those older than 75 years expected to be most affected, according to new data published in Nature Medicine.

A novel statistical model may be a reliable method to predict the age of onset for both mild cognitive impairment and Alzheimer’s disease-related dementia, according to research published in JAMA Network Open.

Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests should only be ordered if the results will directly impact care, like when determining treatment eligibility.

Placental growth factor, a blood-based protein, may be a reliable method to detect abnormalities in the brain that presage cognitive impairment indicative of Alzheimer’s disease, data show.

Younger age at type 2 diabetes diagnosis was significantly associated with elevated dementia risk, especially for individuals with obesity, according to results published in PLOS One.

A new guideline published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association summarizes best practices for specialists and primary care providers on how to evaluate patients with suspected Alzheimer’s disease or related disorders.